Savara Inc (NASDAQ:SVRA) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its holdings in shares of Savara Inc (NASDAQ:SVRA) by 14.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 41,250 shares of the company’s stock after purchasing an additional 5,335 shares during the period. The Manufacturers Life Insurance Company’s holdings in Savara were worth $166,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in SVRA. CANADA LIFE ASSURANCE Co acquired a new stake in Savara during the 1st quarter worth about $35,000. Choreo LLC acquired a new stake in shares of Savara during the second quarter worth about $59,000. DRW Securities LLC purchased a new stake in Savara in the second quarter valued at approximately $62,000. Principal Financial Group Inc. increased its holdings in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares during the period. Finally, Profund Advisors LLC acquired a new position in Savara in the 2nd quarter worth approximately $105,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SVRA has been the topic of several recent research reports. Oppenheimer upped their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Savara in a research note on Tuesday, October 8th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Tuesday, October 1st. Finally, Guggenheim upped their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $11.17.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.76 on Friday. The stock’s 50-day simple moving average is $4.18 and its 200-day simple moving average is $4.35. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The firm has a market capitalization of $519.59 million, a PE ratio of -10.16 and a beta of 0.96. Savara Inc has a fifty-two week low of $3.12 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, equities research analysts forecast that Savara Inc will post -0.44 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.